TY - JOUR
T1 - Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA
AU - Garfein, Richard S.
AU - Liu, Lin
AU - Cuevas-Mota, Jazmine
AU - Collins, Kelly
AU - Muñoz, Fatima
AU - Catanzaro, Donald G.
AU - Moser, Kathleen
AU - Higashi, Julie
AU - Al-Samarrai, Teeb
AU - Kriner, Paula
AU - Vaishampayan, Julie
AU - Cepeda, Javier
AU - Bulterys, Michelle A.
AU - Martin, Natasha K.
AU - Rios, Phillip
AU - Raab, Fredric
N1 - Funding Information:
This study was funded by a grant from the California HealthCare Foundation. J.C. was funded by National Institutes of Health grant no. K01-DA043421. N.K.M. was funded by National Institutes of Health grant no. R01-DA037773 and the University of California–San Diego (USCD) Center for AIDS Research grant no. P30-AI036214.
Funding Information:
grant no. K01-DA043421. N.K.M. was funded by National Institutes of Health grant no. R01-DA037773 and the University of California–San Diego (USCD) Center for AIDS Research grant no. P30-AI036214.
Funding Information:
This study was funded by a grant from the California HealthCare Foundation. J.C. was funded by National Institutes of Health
Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2018/10
Y1 - 2018/10
N2 - We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%– 89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT.
AB - We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%– 89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT.
UR - http://www.scopus.com/inward/record.url?scp=85053612910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053612910&partnerID=8YFLogxK
U2 - 10.3201/eid2410.180459
DO - 10.3201/eid2410.180459
M3 - Article
C2 - 30226154
AN - SCOPUS:85053612910
SN - 1080-6040
VL - 24
SP - 1806
EP - 1815
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 10
ER -